

Express Mail Label No. EL585230615US

Date of Deposit: October 10, 2001



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/925,911	08/09/2001	Samuel Weiss	17810-705 (CTI-N5 DIV11CO

MINTZ LEVIN
One Financial Center
Boston, MA 02111



CONFIRMATION NO. 5125

FORMALITIES LETTER



OC000000006513910

Date Mailed: 09/05/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52 because:
 - Papers contain improper margins. *Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4")*
- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

09/05/2001 10:05:00

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

099591-10101
FOOT" 165260

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ART UNIT:	Not Yet Assigned	EXAMINER:	Not Yet Assigned
APPLICANTS:	Weiss et al.		
SERIAL NO:	09/925,911		
FILING DATE:	August 9, 2001		
FOR :	IN VITRO AND IN VIVO PROLIFERATION AND USE OF MULTIPOTENT STEM CELLS AND THEIR PROGENY		

October 10, 2001
Boston, Massachusetts


Assistant Commissioner for Patents
Washington, D.C. 20231

STATEMENT IN SUPPORT OF SUBSTITUTE SPECIFICATION

Pursuant to 37 CFR 1.125(b)(1), I hereby state that the content of the substitute specification and the specification filed on August 9, 2001 are the same. Applicants hereby submit this substitute specification in response to the Notice to File Corrected Application Papers mailed on September 5, 2001, which specifically requested a substitute specification in compliance with 37 CFR 1.52. The correction of the margins is the only amendment made to the specification at this time. Thus, this submission includes no new matter.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-0311, Ref. No. 17810-705 (CTI-N5 DIV11CON).


Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Christina V. Karnakis, Reg. No. 45,899
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

FOOTNOTES

Express Mail Label No. EL585230615US
Date of Deposit: October 10, 2001



PATENT
Attorney Docket No: 17810-705 (CTI-N5 DIV11CON)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ART UNIT:	Not Yet Assigned	EXAMINER:	Not Yet Assigned
APPLICANTS:	Weiss et al.		
SERIAL NO:	09/925,911		
FILING DATE:	August 9, 2001		
FOR :	IN VITRO AND IN VIVO PROLIFERATION AND USE OF MULTIPOTENT STEM CELLS AND THEIR PROGENY		

October 10, 2001
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS


In response to the Notice To File Corrected Application Papers mailed September 5, 2001, Applicants submit herein a Substitute Specification (110 pages); paper copy of Sequence Listing (4 pages); computer readable form of Sequence Listing (1 disk); Statement in Support of Sequence Listing (1 page); Statement in Support of Substitute Specification (1 page); Preliminary Amendment (5 pages); Request for Corrected Filing Receipt and copy Filing Receipt marked to show changes (4 pages).

Applicants additionally submit herewith a copy of the Supplemental Oath (4 pages) that was filed on March 31, 1999. This Supplemental Oath was filed to reflect the fact that Drs. Joseph Hammang and E. Edward Baetge were not the inventors of the invention claimed in the parent case following the Response to Restriction Requirement filed on December 26, 1996.

FOOTNOTES

This response is due on or before November 5, 2001. Although Applicants believe no fees are due with this filing, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 17810-705 (CTI-N5 DIV11CON).

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Christina V. Karnakis, Reg. No. 45,899

Attorneys for Applicants

c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

TRA 1565642v1

FOOTNOTES